Sugi Predict

Sugi Predict / Targets / PARP15

PARP15

Protein mono-ADP-ribosyltransferase PARP15 · Q460N3 · PARP15 on Sugi Atlas →

31,318 patent compounds predicted against PARP15, 19,242 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Tricyclazole Tricyclazole (SCHEMBL23082) 0.66 16/20
SCHEMBL408480 SCHEMBL408480 0.59 7/20
SCHEMBL348202 SCHEMBL348202 0.58 7/20
SCHEMBL422013 SCHEMBL422013 1.00 6/20
SCHEMBL201939 SCHEMBL201939 0.67 6/20
SCHEMBL81903 SCHEMBL81903 0.58 6/20
SCHEMBL385757 SCHEMBL385757 0.58 6/20
SCHEMBL189795 SCHEMBL189795 0.50 6/20
SCHEMBL540837 SCHEMBL540837 0.64 5/20
Terephthalamide Terephthalamide (SCHEMBL197479) 0.59 5/20
Terephthalamide Terephthalamide (SCHEMBL472214) 0.59 5/20
SCHEMBL77571 SCHEMBL77571 0.57 5/20
SCHEMBL154421 SCHEMBL154421 0.57 5/20
SCHEMBL255654 SCHEMBL255654 0.55 5/20
Terephthalamide Terephthalamide (SCHEMBL250831) 0.54 5/20
SCHEMBL507870 SCHEMBL507870 0.54 5/20
SCHEMBL507869 SCHEMBL507869 0.52 5/20
SCHEMBL438047 SCHEMBL438047 0.49 5/20
SCHEMBL507534 SCHEMBL507534 0.47 5/20
SCHEMBL416244 SCHEMBL416244 0.72 4/20

Clinical trials — most relevant to PARP15 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer PHASE2COMPLETED
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial PHASE2RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors PHASE1COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems PHASE1WITHDRAWN
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Sirtuin1 in COVID19 Patients nanUNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle nanCOMPLETED
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PARP15 binder may also engage these)

ProteinNameSimilarity
Q8CAS9 — 0.997 Q8CAS9 →
PARP9 Protein mono-ADP-ribosyltransferase PARP9 0.987 landscape →
PARP14 Protein mono-ADP-ribosyltransferase PARP14 0.985 landscape →
Q5K651 — 0.984 Q5K651 →
Q8IVG5 — 0.982 Q8IVG5 →
Q6P6V7 — 0.982 Q6P6V7 →
Q5ZJM3 — 0.981 Q5ZJM3 →
DAPK1 Death-associated protein kinase 1 0.981 landscape →
Q2EMV9 — 0.981 Q2EMV9 →
Q80YE7 — 0.981 Q80YE7 →
Q60629 — 0.980 Q60629 →
EPHA6 Ephrin type-A receptor 6 0.980 landscape →
Q8C8H8 — 0.980 Q8C8H8 →
DNM2 Dynamin-2 0.979 landscape →
Q6DDZ9 — 0.979 Q6DDZ9 →
Q5ZIJ9 — 0.979 Q5ZIJ9 →
Q9UII4 — 0.979 Q9UII4 →
Q8NBH2 — 0.979 Q8NBH2 →
Q8GT06 — 0.979 Q8GT06 →
B7ZC32 — 0.979 B7ZC32 →
Q9TTH8 — 0.979 Q9TTH8 →
P20591 — 0.979 P20591 →
Q63406 — 0.979 Q63406 →
P19687 — 0.979 P19687 →
Q91ZY8 — 0.978 Q91ZY8 →
Q69LX2 — 0.978 Q69LX2 →
P25799 — 0.978 P25799 →
Q69ZS7 — 0.978 Q69ZS7 →
Q64691 — 0.978 Q64691 →
Q6AXM7 — 0.978 Q6AXM7 →